Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$329.21M |
$11.74
-0.84%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$327.13M |
$2.03
-4.69%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$320.86M |
$6.37
-0.16%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$314.65M |
$8.81
+0.46%
|
|
TOI
The Oncology Institute, Inc.
Radiopharmaceutical therapy is a modality offered in their oncology practice.
|
$313.24M |
$3.35
-0.15%
|
|
AMRN
Amarin Corporation plc
Amarin's flagship product VASCEPA/icosapent ethyl is a cardiovascular drug indicated to reduce major adverse cardiovascular events when added to statin therapy, making 'Cardiovascular Drugs' a core category.
|
$307.32M |
$14.86
-0.30%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$306.61M |
$11.69
-0.17%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$304.35M |
$8.23
+1.67%
|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$297.94M |
$5.84
+4.47%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$294.36M |
$4.08
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$290.94M |
$5.39
+1.70%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$283.83M |
$2.62
-1.69%
|
|
ALDX
Aldeyra Therapeutics, Inc.
Lead reproxalap for dry eye disease is an ophthalmic drug, representing a direct product in ophthalmology.
|
$277.32M |
$4.61
+4.54%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$269.82M |
$3.40
-1.02%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$269.58M |
$12.62
-5.51%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$267.90M |
$3.12
-4.14%
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$260.49M |
$5.05
-0.49%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$250.47M |
$17.59
-2.60%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$247.92M |
$2.73
-3.02%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$242.48M |
$4.90
+1.03%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$237.82M |
$5.04
-9.35%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$236.42M |
$0.59
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$233.13M |
$1.92
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$228.40M |
$1.50
+0.67%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
Virtue SAB represents a drug-delivery platform delivering extended-release sirolimus to the vessel wall.
|
$227.69M |
$4.24
+1.56%
|
|
QNCX
Quince Therapeutics, Inc.
Lead asset targets Ataxia-Telangiectasia, a rare disease, aligning Quince with the Rare Diseases biotech investment theme.
|
$226.67M |
$4.28
-2.73%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$225.33M |
$29.27
-2.14%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$222.27M |
$4.63
+3.69%
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$220.74M |
$2.37
+12.09%
|
Showing page 13 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
